205 related articles for article (PubMed ID: 15934873)
1. Emerging drugs in cutaneous T-cell lymphomas.
Dummer R
Expert Opin Emerg Drugs; 2005 May; 10(2):381-92. PubMed ID: 15934873
[TBL] [Abstract][Full Text] [Related]
2. Standard and experimental therapy in cutaneous T-cell lymphomas.
Dummer R; Cozzio A; Meier S; Beyeler M; Laetsch B; Doebbeling U; Urosevic M
J Cutan Pathol; 2006 Feb; 33 Suppl 1():52-7. PubMed ID: 16412213
[TBL] [Abstract][Full Text] [Related]
3. New and experimental skin-directed therapies for cutaneous lymphomas.
Farkas A; Kemeny L; French LE; Dummer R
Skin Pharmacol Physiol; 2009; 22(6):322-34. PubMed ID: 19786826
[TBL] [Abstract][Full Text] [Related]
4. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract][Full Text] [Related]
5. Bexarotene gel: a new skin-directed treatment option for cutaneous T-cell lymphomas.
Martin AG
J Drugs Dermatol; 2003 Apr; 2(2):155-67. PubMed ID: 12852367
[TBL] [Abstract][Full Text] [Related]
6. Vorinostat (Zolinza) for cutaneous T-Cell lymphoma.
Med Lett Drugs Ther; 2007 Mar; 49(1256):23-4. PubMed ID: 17351559
[No Abstract] [Full Text] [Related]
7. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
8. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas.
Watanabe T
Expert Opin Investig Drugs; 2010 Sep; 19(9):1113-27. PubMed ID: 20649502
[TBL] [Abstract][Full Text] [Related]
9. Emerging drugs for the treatment of myelodysplastic syndrome.
Nivatpumin PJ; Gore SD
Expert Opin Emerg Drugs; 2005 Aug; 10(3):569-90. PubMed ID: 16083330
[TBL] [Abstract][Full Text] [Related]
10. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
11. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas.
Zain J; Kaminetzky D; O'Connor OA
Expert Rev Hematol; 2010 Apr; 3(2):187-203. PubMed ID: 21083462
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the management of cutaneous lymphomas.
Belloni B; Johansen N; Glass LF; Dummer R
Semin Oncol; 2012 Apr; 39(2):150-62. PubMed ID: 22484187
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat.
Grant S; Easley C; Kirkpatrick P
Nat Rev Drug Discov; 2007 Jan; 6(1):21-2. PubMed ID: 17269160
[No Abstract] [Full Text] [Related]
14. Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomas.
Urosevic M
Curr Opin Investig Drugs; 2007 Jun; 8(6):493-8. PubMed ID: 17621880
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma.
Ellis L; Pan Y; Smyth GK; George DJ; McCormack C; Williams-Truax R; Mita M; Beck J; Burris H; Ryan G; Atadja P; Butterfoss D; Dugan M; Culver K; Johnstone RW; Prince HM
Clin Cancer Res; 2008 Jul; 14(14):4500-10. PubMed ID: 18628465
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cutaneous T-cell lymphoma with retinoids.
Zhang C; Duvic M
Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
[TBL] [Abstract][Full Text] [Related]
17. Skin directed therapy for mycosis fungoides: a review.
Berthelot C; Rivera A; Duvic M
J Drugs Dermatol; 2008 Jul; 7(7):655-66. PubMed ID: 18664158
[TBL] [Abstract][Full Text] [Related]
18. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
19. [Development of targeted treatments for cutaneous T cell lymphomas].
Bagot M
Bull Acad Natl Med; 2012 Mar; 196(3):631-40; discussion 640-1, 653-4. PubMed ID: 23472352
[TBL] [Abstract][Full Text] [Related]
20. Vorinostat for the treatment of bullous pemphigoid in the setting of advanced, refractory cutaneous T-cell lymphoma.
Gardner JM; Evans KG; Goldstein S; Kim EJ; Vittorio CC; Rook AH
Arch Dermatol; 2009 Sep; 145(9):985-8. PubMed ID: 19770436
[No Abstract] [Full Text] [Related]
[Next] [New Search]
